Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Non Operating Income (2021 - 2025)

Historic Non Operating Income for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $256000.0.

  • Lyra Therapeutics' Non Operating Income fell 5555.56% to $256000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 3826.2%. This contributed to the annual value of $3.0 million for FY2024, which is 3438.54% down from last year.
  • As of Q3 2025, Lyra Therapeutics' Non Operating Income stood at $256000.0, which was down 5555.56% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Lyra Therapeutics' Non Operating Income ranged from a high of $1.4 million in Q2 2025 and a low of $14000.0 during Q1 2022
  • Its 5-year average for Non Operating Income is $554684.2, with a median of $435000.0 in 2024.
  • Its Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 755714.29% in 2023, then plummeted by 7255.99% in 2025.
  • Quarter analysis of 5 years shows Lyra Therapeutics' Non Operating Income stood at $21000.0 in 2021, then surged by 4342.86% to $933000.0 in 2022, then soared by 43.41% to $1.3 million in 2023, then crashed by 67.49% to $435000.0 in 2024, then crashed by 41.15% to $256000.0 in 2025.
  • Its Non Operating Income was $256000.0 in Q3 2025, compared to $1.4 million in Q2 2025 and $298000.0 in Q1 2025.